Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Mehrdad Alemozaffar et al.|The Lancet Oncology|2020Cited by 459
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M. Narayan, Colin P. Dinney, Stephen A. Boorjian et al.|The Journal of Urology|2024Cited by 80
Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial DesignJustin T. Matulay, Ashish M. Kamat, Roger Li et al.|The Journal of Urology|2021Cited by 70
The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overviewNathan A. Brooks, Ashish M. Kamat, Helen Zafirakis et al.|BJUI Compass|2020Cited by 10
Reply by AuthorsJustin T. Matulay, Ashish M. Kamat, Roger Li et al.|The Journal of Urology|2021Cited by 0